Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus ZITHROMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus ZITHROMAX.
ERYTHROMYCIN ESTOLATE vs ZITHROMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
Azithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing translocation of peptides. It also has immunomodulatory and anti-inflammatory effects.
250-500 mg orally every 6-12 hours
500 mg orally once daily for 3 days, or 2 g orally as a single dose for certain infections.
None Documented
None Documented
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
Terminal elimination half-life of approximately 68 hours (range 35-96 hours), allowing once-weekly dosing for some indications.
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Primarily eliminated via biliary/fecal route (∼50-60% as unchanged drug); renal excretion accounts for ∼12% of the dose; minimal metabolism.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic